In response to combination therapy, CXCL13 produced by ASPH+ expressing HCC or TNBC cell was capable of recruiting immune cells, especially CXCR5+/CD8+ TILs (including a proportion of CTLs), to participate in forming TLSs and to execute cytotoxicity against cancer cells. The gene discussed is CD8A; the disease is cancer.